StoxBiocon vs Anthem Biosciences: share price & financials comparison
NSE: BIOCON vs ANTHEM · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Biocon vs Anthem Biosciences at a glance
Biocon (BIOCON) has a market capitalisation of ₹59,326 Cr, against ₹52,800 Cr for Anthem Biosciences (ANTHEM). Over the past year Anthem Biosciences has returned +33.4%, compared with -4.3% for Biocon. On valuation, Biocon trades at a lower P/E of 131.2 versus 278.2. Anthem Biosciences earns a higher return on equity (5.8% vs 1.3%). Biocon comes out ahead on valuation. Anthem Biosciences comes out ahead on size, profitability, growth, financial health, momentum and technicals. Across the scored metrics below, Biocon leads on 2 and Anthem Biosciences on 10. On StoxGud's 10-point checklist, Biocon scores 2/10 and Anthem Biosciences scores 6/10.
| Metric | Biocon | Anthem Biosciences |
|---|---|---|
| Size | ||
| Market cap | ₹59,326 Cr | ₹52,800 Cr |
| Revenue (latest FY) | ₹16,927 Cr | ₹2,124 Cr |
| Net profit (latest FY) | ₹386 Cr | ₹592 Cr |
| Valuation | ||
| P/E | 131.2 | 278.2 |
| P/B | 1.70 | 16.09 |
| Dividend yield | 0.15% | — |
| Profitability | ||
| Return on equity | 1.3% | 5.8% |
| Net profit margin | 2.6% | 9.3% |
| Operating margin | 20.3% | 41.4% |
| Growth | ||
| Revenue growth (YoY) | +2.2% | +8.0% |
| Net profit growth (YoY) | -51.1% | — |
| Revenue CAGR (multi-year) | +19.0% | — |
| Financial health | ||
| Debt to equity | 0.43 | 0.01 |
| Momentum | ||
| 1-month return | +3.7% | +7.7% |
| 1-year return | -4.3% | +33.4% |
| 3-year CAGR | +17.0% | — |
| 5-year CAGR | +0.1% | — |
| 10-year CAGR | +9.8% | — |
| Distance from 52W high | -17.4% | -2.2% |
| Technicals | ||
| RSI (14) | 76 | 84 |
| Price vs 200-day avg | -6.7% | +20.2% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Biocon | Anthem Biosciences |
|---|---|---|
| Price above 50-day average | ✗ | ✓ |
| Price above 200-day average | ✗ | ✓ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✗ | ✓ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✗ |
| P/E below industry median | ✗ | ✗ |
| Score | 2/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Biocon or Anthem Biosciences?
Biocon has a market cap of ₹59,326 Cr and Anthem Biosciences has a market cap of ₹52,800 Cr as of 13 Nov 2026.
Which has a lower P/E, Biocon or Anthem Biosciences?
Biocon has the lower P/E: Biocon trades at 131.2 and Anthem Biosciences at 278.2.
Which gave better returns in the last year, Biocon or Anthem Biosciences?
Anthem Biosciences did better: Biocon returned -4.3% and Anthem Biosciences returned +33.4% over one year.
What is the difference between Biocon and Anthem Biosciences?
Both are NSE-listed companies in Healthcare. They are about the same size by market cap (₹59,326 Cr vs ₹52,800 Cr). In the latest financial year Biocon reported revenue of ₹16,927 Cr and Anthem Biosciences ₹2,124 Cr. Operating margin is 20.3% for Biocon and 41.4% for Anthem Biosciences. Debt to equity is 0.43 for Biocon and 0.01 for Anthem Biosciences.
Which is better, Biocon or Anthem Biosciences?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Biocon leads on 2 and Anthem Biosciences on 10. Biocon is ahead on valuation. Anthem Biosciences is ahead on size, profitability, growth, financial health, momentum and technicals. On StoxGud's rules-based checklist Biocon scores 2/10 and Anthem Biosciences scores 6/10. This is information, not advice: consult a SEBI-registered adviser before investing.